News

Filter

Current filters:

AlpharadinResearch

Bayer and Algeta’s Alpharadin efficacy confirmed; Almirall to market Xarelto in Spain

13-02-2012

German drug major Bayer (BAY: DE) and Norwegian partner Algeta (OSE: ALGETA) announced that the survival…

AlgetaAlmirallAlpharadinBayerCardio-vascularEuropeMarkets & MarketingOncologyPharmaceuticalRegulationResearchXarelto

Bayer boasts four potential pipeline blockbusters

21-12-2011

German drugs and crop and material sciences group Bayer (BAT: DE) said yesterday that it plans to continue…

AlpharadinBayerCardio-vascularEyleaFinancialMarkets & MarketingOncologyOphthalmicsPharmaceuticalregorafenibResearchXarelto

News briefs from breast cancer meeting

12-12-2011

In further news from the the San Antonio Breast Cancer Symposium (SABCS) that took place in Texas, USA…

AlgetaAlpharadinBayerGlaxoSmithKlineOncologyPharmaceuticalResearchTykerb

Positive first Phase III trial of an alpha-pharmaceutical, Bayer’s Alpharadin

26-09-2011

Until recently, options for patients with bone metastases from advanced prostate cancer have been very…

AlgetaAlpharadinBayerOncologyPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top